Biased signaling: Potential agonist and antagonist of PAR2

Journal of Biomolecular Structure and Dynamics

Volumn 34, Issue 6, 2015, Pages 1363-1376

  Kakarala, Kavita Kumari ^a   Jamil, Kaiser ^a  

^a JNT University Anantapur   (India)

Author keywords

Agonist; Antagonist; Biased signaling; Breast cancer; Ensemble docking

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; LIGAND; NEUROKININ 1 RECEPTOR ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 AGONIST; PROTEINASE ACTIVATED RECEPTOR 2 ANTAGONIST; SEROTONIN 1 AGONIST; SEROTONIN 2 ANTAGONIST; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; PROTEIN BINDING;

ARTICLE; COMPUTER MODEL; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; CONFORMATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECTS; MOLECULAR DOCKING; MOLECULAR MODEL; PROCEDURES;

BINDING SITES; DRUG DESIGN; DRUG DISCOVERY; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; RECEPTOR, PAR-2; SIGNAL TRANSDUCTION;

EID: 84984981936     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2015.1079556     Document Type: Article

References (63)

1. Alonso, N., Monczor, F., Echeverría, E., Davio, C., Shayo, C., & Fernández, N. (2014). Signal transduction mechanism of biased ligands at histamine H2 receptors. Biochemical Journal, 459, 117-126.
2. Bachelerie, F., Ben-Baruch, A., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Zlotnik, A. (2014). Chemo-kine receptors, introduction. Retrieved October 31, from IUPHAR/BPS Guide to PHARMACOLOGY. http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId
3. Bäck, M., Shimizu, T., Yokomizo, T., Rovati, G. E., Serhan, C. N., Dahlén, S. E., Powell, W. (2013). Leukotriene receptors, introduction. Retrieved October 8, 2013, from http://www.iuphar-db.org/DATABASE/FamilyIntroduc tionForward?familyId=35
4. Barrington, W. W., Jacobson, K. A., & Stiles, G. L. (1989). Demonstration of distinct agonist and antagonist conformations of the A1 adenosine receptor. Journal of Biological Chemistry, 264, 13157-13164.
5. Berger, A. (2000). PAR2 antagonists - The next generation of anti-inflammatories? British Medical Journal, 320, 334.
6. Capra, V., Ravasi, S., Accomazzo, M. R., Citro, S., Grimoldi, M., Abbracchio, M. P., & Rovati, G. E. (2005). CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: A possible feedback mechanism in inflammation. Journal of Cell Science, 118, 5625-5636.
7. Cavasotto, C. N., Orry, A. J. W., Murgolo, N. J., Czarniecki, M. F., Kocsi, S. A., Hawes, B. E., Monsma, F. J. (2008). Discovery of novel antagonist chemotypes to a G-protein coupled receptor through ligand-steered homology modeling and structure-based virtual screening. Journal of Medicinal Chemistry, 51, 581-588.
8. Charfi, I., Audet, N., Bagheri Tudashki, H., & Pineyro, G. (2015). Identifying ligand-specific signalling within biased responses: Focus on δ opioid receptor ligands. British Journal of Pharmacology, 172, 435-448.
9. Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Richardson, D. C. (2010). MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallographica, D66, 12-21.
10. Ciana, P., Fumagalli, M., Trincavelli, M. L., Verderio, C., Rosa, P., Lecca, D., Abbracchio, M. P. (2006). The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. The EMBO Journal, 25, 4615-4627.
11. Diaz, P., Phatak, S., Xu, J., Diaz, F.-A., Cavasotto, C. N., & Naguib, M. (2009a). 6-methoxy-n-alkyl isatin acylhydra-zone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: Design, synthesis, and binding mode prediction. Journal of Medicinal Chemistry, 52, 433-444.
12. Diaz, P., Phatak, S. S., Xu, J., Fronczek, F., Astruc-Diaz, F., Thompson, C., Naguib, M. (2009b). 2,3-dihydro-1-ben-zofuran derivatives as a novel series of potent selective cannabinoid receptor 2 agonists: Design, synthesis, and binding mode prediction through ligand-steered modeling. ChemMedChem, 4, 1615-1629.
13. Deupi, X., & Kobilka, B. K. (2010). Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda), 25, 293-303.
14. Eswar, N., Eramian, D., Webb, B., Shen, M. Y., & Sali, A. (2008). Protein structure modeling with MODELLER. Methods in Molecular Biology, 426, 145-159.
15. Fernandes, L., Fortes, Z. B., Nigro, D., Tostes, R. C., Santos, R. A., & Catelli De Carvalho, M. H. (2001). Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension, 37, 703-709.
16. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Shenkin, P. S. (2004). Glide: A new approach for rapid, accurate docking and scoring. Method and assessment of docking accuracy. Journal of Medicinal Chemistry, 47, 1739-1749.
17. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. Journal of Medicinal Chemistry, 49, 6177-6196.
18. Garza, L. A., Liu, Y., Yang, Z. Z., Alagesan, B., Lawson, J. A., Norberg, S. M., Cotsarelis, G. (2012). Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Science Translational Medicine, 4, 126ra34. doi:10.1126/scitranslmed.3003122
19. Gatica, E. A., & Cavasotto, C. N. (2012). Ligand and decoy sets for docking to G protein-coupled receptors. Journal of Chemical Information and Modeling, 52(1), 1-6.
20. Hassan, I., & Haji, M. L. (2014). Understanding itch: An update on mediators and mechanisms of pruritus. Indian Journal of Dermatology, Venereology and Leprology, 80, 106-114.
21. Hollenberg, M. D., & Compton, S. J. (2002). International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacological Reviews, 54, 203-217.
22. Hollenberg, M. D., Mihara, K., Polley, D., Suen, J. Y., Han, A., Fairlie, D. P., & Ramachandran, R. (2014). Biased signalling and proteinase-activated receptors (PARs): Targeting inflammatory disease. British Journal of Pharmacology, 171, 1180-1194.
23. Holst, B., Mokrosinski, J., Lang, M., Brandt, E., Nygaard, R., Frimurer, T. M., Schwartz, T. W., (2007). Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. Journal of Biological Chemistry, 282, 15799-15811.
24. Jaakola, V. P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y., Lane, J. R., Stevens, R. C. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 322, 1211-1217.
25. Kahsai, A. W., Xiao, K., Rajagopal, S., Ahn, S., Shukla, A. K., Sun, J., Lefkowitz, R. J. (2011). Multiple ligand-specific conformations of the β2-adrenergic receptor. Nature Chemical Biology, 7, 692-700. doi:10.1038/nchembio.634
26. Kakarala, K. K., Jamil, K., & Devaraji, V. (2014). Structure and putative signaling mechanism of protease activated receptor 2 (PAR2) - A promising target for breast cancer. Journal of Molecular Graphics and Modelling, 53, 179-199.
27. Kenakin, T. (2002). Efficacy at G-protein-coupled receptors. Nature Reviews Drug Discovery, 1, 103-110.
28. Kenakin, T. (2011). Functional selectivity and biased receptor signaling. Journal of Pharmacology and Experimental Therapeutics, 336, 296-302.
29. Kenakin, T. K. (2012). Biased signalling and allosteric machines: New vistas and challenges for drug discovery. British Journal of Pharmacology, 165, 1659-1669.
30. Kuntal, B. K., Aparoy, P., & Reddanna, P. (2010). EasyModeller: A graphical interface to MODELLER. BMC Research Notes, 3, 226. doi:10.1186/1756-0500-3-226
31. Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (2005). PROCHECK: A program to check the stereo chemical quality of protein structures. Journal of Applied Crystallography, 26, 283-291.
32. Li, Z., Zhang, X. J., Xu, H. X., Sung, J. J., & Bian, Z. X. (2009). Intracolonical administration of protease-activated receptor-2 agonists produced visceral hyperalgesia by upregulating serotonin in the colon of rats. European Journal of Pharmacology, 606, 199-204.
33. Liu, Y., & Mueller, B. M. (2006). Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochemical and Biophysical Research Communications, 344, 1263-1270. Epub 2006 Apr 19.
34. Macfarlane, S. R., Seatter, M. J., Kanke, T., Hunter, G. D., & Plevin, R. (2001). Proteinase-activated receptors. Pharmacological Reviews, 53, 245-282.
35. Magnusson, C., Liu, J., Ehrnström, R., Manjer, J., Jirström, K., Andersson, T., & Sjölander, A. (2011). Cysteinyl leuko-triene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. International Journal of Cancer, 129, 9-22.
36. Matej, R., Mandakova, P., Netikova, I., Pouckova, P., & Olejar, T. (2007). Proteinase-activated receptor-2 expression in breast cancer and the role of trypsin on growth and metabolism of breast cancer cell line MDAMB-231. Physiological Research, 56, 475-484.
37. Maudsley, S., Patel, S. A., Park, S. S., Luttrell, L. M., & Martin, B. (2012). Functional signaling biases in G protein-coupled receptors: Game theory and receptor dynamics. Mini-reviews in Medicinal Chemistry, 12, 831-840.
38. Morris, D. R., Ding, Y., Ricks, T. K., Gullapalli, A., Wolfe, B. L., & Trejo, J. (2006). Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Research, 66, 307-314.
39. Nonaka, Y., Hiramoto, T., & Fujita, N. (2005). Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochemical and Biophysical Research Communications, 337, 281-288.
40. Nystedt, S., Emilsson, K., Wahlestedt, C., & Sundelin, J. (1994). Molecular cloning of a potential proteinase activated receptor. Proceedings of the National Academy of Sciences, 91, 9208-9212.
41. Orry, A. J. W., Abagyan, R., & Cavasotto, C. N. (2006). Structure-based development of target-specific compound libraries. Drug Discovery Today, 11, 261-266.
42. Perez, D. M., & Karnik, S. S. (2005). Multiple signaling states of G-protein-coupled receptors. Pharmacological Reviews, 57, 147-161.
43. Phatak, S. S., Gatica, E. A., & Cavasotto, C. N. (2010). Ligand-steered modeling and docking: A benchmarking study in class A G-protein-coupled receptors. Journal of Chemical Information and Modeling, 50, 2119-2128.
44. Phatak, S. S., Stephan, C. C., & Cavasotto, C. N. (2009). High-throughput and in silico screenings in drug discovery. Expert Opinion on Drug Discovery, 4, 947-959.
45. Preininger, A. M., Meiler, J., & Hamm, H. E. (2013). Conformational flexibility and structural dynamics in GPCR-mediated G protein activation: A perspective. Journal of Molecular Biology, 425, 2288-2298.
46. Ramachandran, R., & Hollenberg, M. D. (2008). Proteinases and signalling: Pathophysio-logical and therapeutic implications via PARs and more. British Journal of Pharmacology, 153, S263-S282.
47. Rasmussen, U. B., Gachet, C., Schlesinger, Y., Hanau, D., Ohlmann, P., Van Obberghen-Schilling, E., Pavirani, A. (1993). A peptide ligand of the human thrombin receptor antagonizes alpha-thrombin and partially activates platelets. Journal of Biological Chemistry, 268, 14322-14328.
48. Raval, A., Piana, S., Eastwood, M. P., Dror, R. O., & Shaw, D. E. (2012). Refinement of protein structure homology models via long, all-atom molecular dynamics simulations. Proteins, 80, 2071-2079.
49. Reiner, S., Ambrosio, M., Hoffmann, C., & Lohse, M. J. (2010). Differential signaling of the endogenous agonists at the 2-adrenergic receptor. Journal of Biological Chemistry, 285, 36188-36198.
50. Sastry, M., Lowrie, J. F., Dixon, S. L., & Sherman, W. (2010). Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. Journal of Chemical Information and Modeling, 50, 771-784.
51. Staus, D. P., Wingler, L. M., Strachan, R. T., Rasmussen, S. G., Pardon, E., Ahn, S., Lefkowitz, R. J. (2014). Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. Molecular Pharmacology, 85, 472-481.
52. Storey, R. F., Judge, H. M., Wilcox, R. G., & Heptinstall, S. (2002). Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thrombosis and Haemostasis, 88, 488-494.
53. Su, X., Camerer, E., Hamilton, J. R., Coughlin, S. R., & Matthay, M. A. (2005). Protease-activated receptor-2 activation induces acute lung inflammation by neuropeptide-dependent mechanisms. The Journal of Immunology, 175, 2598-2605.
54. Su, S., Li, Y., Luo, Y., Sheng, Y., Su, Y., Padia, R. N., Huang, S. (2009). Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene, 28, 3047-3057.
55. Suen, J. Y., Barry, G. D., Lohman, R. J., Halili, M. A., Cotterell, A. J., Le, G. T., & Fairlie, D. P. (2012). Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). British Journal of Pharmacology, 165, 1413-1423.
56. Suen, J. Y., Gardiner, B., Grimmond, S., & Fairlie, D. P. (2010). Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS One, 5, e13809. doi:10.1371/journal.pone.0013809
57. Tanaka, H., Yoshida, T., Miyamoto, N., Motoike, T., Kurosu, H., Shibata, K., Yanagisawa, M. (2003). Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. Proceedings of the National Academy of Sciences, 100, 6251-6256.
58. Tautermann, C. S., Seeliger, D., & Kriegl, J.M. (2015). What can we learn from molecular dynamics simulations for GPCR drug design? Computational and Structural Biotechnology Journal, 13, 111-121.
59. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Mailman, R. B. (2007). Functional selectivity and classical concepts of quantitative pharmacology. Journal of Pharmacology and Experimental Therapeutics, 320(1), 1-13.
60. Warszycki, D., Mordalski, S., Kristiansen, K., Kafel, R., Sylte, I., Chilmonczyk, Z., & Bojarski, A. J. (2013). A linear combination of pharmacophore hypotheses as a new tool in search of new active compounds - An application for 5-HT1A receptor ligands. PLoS One, 8, e84510. doi:10.1371/journal.pone.0084510
61. Wiederstein, Sippl. (2007). ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research, 35, W407-W410.
62. Yosten, G. L., Kolar, G. R., Redlinger, L. J., & Samson, W. K. (2013). Evidence for an interaction between proinsulin C-peptide and GPR146. Journal of Endocrinology, 218, B1-B8.
63. Zhang, C., Srinivasan, Y., Arlow, D. H., Fung, J. J., Palmer, D., Zheng, Y., Kobilka, B. K. (2012). High-resolution crystal structure of human protease-activated receptor 1. Nature, 492, 387-392.